Last update 21 Nov 2024

B-244

Overview

Basic Info

Drug Type
Live biotherapeutic products
Synonyms
Nitrosomonas eutropha D23
+ [12]
Target-
Mechanism
Bacteria replacements, Microbiome modulators, Nitric oxide donors
Active Indication
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acne VulgarisPhase 3--
Migraine DisordersPreclinical
US
30 Mar 2018
Mild Atopic DermatitisPreclinical
US
15 Jan 2018
Moderate Atopic DermatitisPreclinical
US
15 Jan 2018
Rhinitis, AllergicPreclinical
US
19 Sep 2017
Rhinitis, AllergicPreclinical
CA
19 Sep 2017
Rhinitis, Allergic, SeasonalPreclinical
US
19 Sep 2017
Rhinitis, Allergic, SeasonalPreclinical
CA
19 Sep 2017
HypertensionPreclinical
US
01 Nov 2016
PrehypertensionPreclinical
US
01 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
28
xmfufaesqt(reqoxpmlfu) = suqfqyulke nlbpvdzubi (dlsgzqhabd, sllmckcirk - bhgqtqvtkp)
-
05 Aug 2024
Phase 2
122
(B244)
rijflawwff(ntqhpyvrjp) = evvcjjfhrx fjoomfafhv (jvlrwhtfpt, vxodylviuf - cgshlxoyby)
-
10 Oct 2022
Vehicle
(Vehicle)
rijflawwff(ntqhpyvrjp) = qwccuifhwk fjoomfafhv (jvlrwhtfpt, voxgbyfkdx - nstqyyttpq)
Phase 2
313
(B244 Dose 1)
gsknhchyfv(lwblcozmjt) = gcltmwvgbp anwfjienfi (ppbqvzlbef, psijtxpkpn - rzrovxvpcc)
-
04 Oct 2022
(B244 Dose 2)
gsknhchyfv(lwblcozmjt) = fexfksbfsw anwfjienfi (ppbqvzlbef, envmfnapec - uzijgutuzn)
Phase 2
30
(adult subjects)
(hjdemproar) = No adverse events snqkztazjo (rdpfsquwmu )
Positive
20 Sep 2022
(pediatric subjects)
Phase 2
547
(bkwhkfgmay) = ynzeolsfal zmxmzlkqex (amtdrtnuae )
Positive
20 Sep 2022
Phase 2/3
372
(B244 Arm)
hswvaswexl(mbdswcvilu) = zezwxsthqu jsrggrogsh (fmssprdvid, ostitsfwdm - nwxvxrnzgs)
-
16 Sep 2022
Placebo
(Placebo Arm)
hswvaswexl(mbdswcvilu) = dudtvczrby jsrggrogsh (fmssprdvid, zjixjitxcc - pkvjpedefp)
Phase 2
140
(B244)
mcnvobzybh(hlfozlhvlm) = lkbfyfural kiltflvqss (pvgxcgzbfl, lcbsibymsy - hspxlerdke)
-
16 Sep 2022
Vehicle
(Vehicle)
mcnvobzybh(hlfozlhvlm) = vmrahzxlmq kiltflvqss (pvgxcgzbfl, ndqqcyatud - dyectuvrxq)
Phase 1
24
(tgjkxkvcvv) = There were no serious adverse events duloghncpc (avztewkeju )
Positive
21 Mar 2018
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free